1st Biotherapeutics, Inc.

The Green Cross Corporation

Institut Pasteur Korea

Qurient Co., Ltd.

Legochem Bioscience Ltd.

Handok Inc.

Jinhwa Lee

Suyeon Jo

Suk Ho Lee

Jae Eun Kim

Jeongmin Kim

Misoon Kim

Keonseung Lim

A Yeong Park

Hee Jeong Seo

Kwang-Seop Song

Myung Eun Jung

Suk Hoon Kang

Min Ju Kim

Eun-Jung Park

Sung-Han Lee

Ae Nim Pae

Mi-Soon Kim

Woo-Kyu Park

Hyun Jung Kim

Minwoo Lee

Younggyu Kong

Jeong Min Kim

Min Woo Lee

Ji-Hyun Park

Young Sam Park

Yong Zu Kim

Ho Young Song

Sung Ho Woo

Tae Kyo Park

Sang Eun Chae

Sangchul Lee

Jaeseung Kim

Seong Jin Kim

Young Lag Cho

Kiyean Nam

Sunhee Kang

SaeYeon Lee

Seungyong Kim

Seung Mook Lim

Jong Yup Kim

Hwajung Nam

Eun Jung Son

Yeonguk Jeon

Gadhe Changdev Gorakshnath

Yejin Hwang

Inyoung Yang

Ho Kyun Han

Wanjun Li

Ki-Nam Lee

Mingzhu Fan

Junwon Lee

Gwibin Lee

Min Jung Seo

Zaesung No

Jeongjun Kim

Sung-Jun Han

Hyeongjun Kim

Gahee Choi

Chong-Hwan Jonathan Chang

Koo Hyeon Ahn

Heekyoung Yang

Jung Hwan Kim

Kwang Woo Ahn

Hyonam Kim

Min-Ah Kim

Min-ah Kim

Kwang-Woo Ahn

Gyooseung Jung

Suk Youn Kang

Dooseop Kim

Doran Kim

Gwi Bin Lee

Hyun Sook Hwang

The present disclosure relates to [F]-labeled imidazopyridine derivatives or salts thereof as positron emission tomography (PET) radiotracers suitable for imaging the stress-signaling non-receptor tyrosine kinase c-abl, and their use in in vivo diagnosis, preclinical and clinical imaging, patient stratification on the basis of mutational status of c-abl and assessing response to therapeutic treatments. The present disclosure further relates to the use of [F]-labeled imidazopyridine derivatives as PET radiotracers. The disclosure also provides a process for the radiosynthesis of [F]-labeled imidazopyridinederivatives.

[F]-labeled imidazopyridine derivatives as PET radiotracer

The present disclosure provides a compound of Formula (I) or pharmaceutically acceptable salt, stereoisomers thereof, a pharmaceutical composition comprising the compound, and a method to treat or prevent inflammatory and autoimmune diseases, especially neuroinflammation diseases using the compound.

Compounds for prevention or treatment of neurodegenerative disorders

The present disclosure provides polymorphic forms and salts of (1S,2S)-2-fluoro-N-(6-(4-methylpyridin-3-yl)benzo[d]thiazol-2-yl)cyclopropane-1-carboxamide, pharmaceutical compositions comprising the compounds, processes for preparation of the compounds, and methods for treating neurodegenerative disorders.

Pharmaceutical salts of benzothiazol compounds, polymorphs and methods for preparation thereof

The present disclosure provides a compound of Formula (I) or pharmaceutically acceptable salts thereof, a composition comprising the compound, methods of using the compound for the treatment of various disorders associated with HPK1, and methods of preparing these compounds.

Substituted indazoles as hematopoietic progenitor kinase 1 (HPK1) inhibitors

The present disclosure provides a compound of Formula (I) or pharmaceutically acceptable salt, stereoisomers thereof, a pharmaceutical composition comprising the compound, and a method to treat or prevent neurodegenerative diseases using the compound.

Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders

The present disclosure provides a compound of Formula (I) or pharmaceutically acceptable salt, stereoisomers thereof, a pharmaceutical composition comprising the compound, and a method for treating or preventing an inflammatory and autoimmune diseases, especially neuroinflammation diseases using the compound.

2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds

The present disclosure provides a compound of Formula (I) or pharmaceutically acceptable salts thereof, a composition comprising the compound, methods of using the compound for the treatment of various disorders associated with HPK1, and methods of preparing these compounds. 

Indazoles as hematopoietic progenitor kinase 1 (HPK1) inhibitors and methods using same

The present disclosure provides a compound of Formula (I) or pharmaceutically acceptable salt, stereoisomers thereof, a pharmaceutical composition comprising the compound, and a method to treat or prevent neurodegenerative diseases using the compound. 

The present disclosure provides a compound of general Formula (I) having c-abl kinase inhibitory activity or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the compound, and a method useful to treat or prevent neurodegenerative diseases using the compound. 

Benzothiazol compounds and methods using the same for treating neurodegenerative disorders

The present disclosure provides a process for preparing (1S,2S)-2-fluoro-N-(6-(4-methylpyridin-3-yl)benzo[d]thiazol-2-yl) cyclopropanecarboxamide or a salt thereof, such as the compound of Formula (I), comprising: reacting Compound 1 as a starting material with Compound 2 in the presence of Pd(dppf)Cland 1,4-dioxane to form Compound 3; reacting Compound 3 with Compound 4 in the presence of HATU and DIPEA to produce Compound 5; and reacting Compound 5 with hydrochloric acid to produced Formula (I).

Processes for preparing benzothiazol compounds and methods of using the same for treating neurodegenerative disorders

The present invention refers to: a compound having the general formula (I), wherein n is 0, 1, 2 or; m is 0, 1, 2 or 3; o is 0, 1, 2 or 3; W, X, Y and Z are independently selected from CH, N or N-oxide; A is NR, C&#x2550;O, C&#x2550;S, OP(O)(O), P&#x2550;O, CH2, or a heteroarly selected from the group consisting of (a), (b), (c), (d), (e), (f), (g); V is C&#x2550;O, O, S, CH, or NR; as well as its use in treating inflammatory diseases such as asthma, COPD, inflammation post infection, arthritis, atherosclerosis, pain and dermatitis. 

Anti-inflammation compounds

The present invention relates to a novel compound with thiophene ring having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes. The prevention also provides a method for preparing same, a pharmaceutical composition containing same, and a method for preventing or treating metabolic disorders, particularly diabetes.

Thiophene derivative as SGLT2 inhibitor and pharmaceutical composition comprising same

The present invention relates to novel arylpiperazine-containing pyrrole 3-carboxamide derivatives of formula (I) or a pharmaceutically acceptable salt thereof which is useful for preventing or treating depressive disorders. The present invention also provides a method for preparing the arylpiperazine-containing pyrrole 3-carboxamide derivatives or the pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and a method for preventing or treating depressive disorders.

Arylpiperazine-containing pyrrole 3-carboxamide derivatives for treating depressive disorders

A novel arylpiperazine-containing imidazole 4-carboxamide derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient for preventing or treating a depressive disorder are provided.

Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same

Growing community of inventors

Yongin-si, South Korea

Jinhwa Lee